Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
RBX2660
Description:
RBX2660 is an investigational microbiota-based therapeutic designed to prevent recurrent Clostridioides difficile infection by restoring gut microbial communities.
Primary topic:
Clostridium difficile and Clostridium perfringens research (83%)
Related topics:
Clostridium difficile and Clostridium perfringens research (83%),
Gut microbiota and health (11%)
OpenAlex ID:
keywords/rbx2660
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
2022
·
Sahil Khanna
, Maha Assi
, et al.
·
Drugs
·
340
PDF
Safety and Durability of RBX2660 (Microbiota Suspension) for RecurrentClostridium difficileInfection: Results of the PUNCH CD Study
2015
·
Robert Orenstein
, Erik Dubberke
, et al.
·
Clinical Infectious Diseases
·
212
Probiotics for prevention of Clostridium difficile infection
2017
·
John P. Mills
, Krishna Rao
, et al.
·
Current Opinion in Gastroenterology
·
193
Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection
2018
·
Erik R Dubberke
, Christine H Lee
, et al.
·
Clinical Infectious Diseases
·
153
PDF
Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study
2021
·
Amy Langdon
, Drew J. Schwartz
, et al.
·
Genome Medicine
·
93
PDF
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
2022
·
Robert Orenstein
, Erik R. Dubberke
, et al.
·
BMC Infectious Diseases
·
90
PDF
Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection
2016
·
Erik R. Dubberke
, Kathleen M. Mullane
, et al.
·
Open Forum Infectious Diseases
·
82
PDF
Restoration of Bacterial Microbiome Composition and Diversity Among Treatment Responders in a Phase 2 Trial of RBX2660: An Investigational Microbiome Restoration Therapeutic
2019
·
Ken F Blount
, William D Shannon
, et al.
·
Open Forum Infectious Diseases
·
72
Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies
2023
·
Anne J. Gonzales-Luna
, Travis J. Carlson
, et al.
·
Gut Microbes
·
71
PDF
Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial
2020
·
Suryang Kwak
, JooHee Choi
, et al.
·
Microbiome
·
66
PDF
Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection
2022
·
Erik R. Dubberke
, Robert Orenstein
, et al.
·
Infectious Diseases and Therapy
·
57
PDF
New and emerging therapies for Clostridium difficile infection
2016
·
Jessica Martin
, Mark Wilcox
·
Current Opinion in Infectious Diseases
·
50
Update on microbiota-derived therapies for recurrent Clostridioides difficile infections
2023
·
Nicolas Benech
, Frédéric Barbut
, et al.
·
Clinical Microbiology and Infection
·
36
PDF
Emerging Options for the Prevention and Management of Clostridioides difficile Infection
2023
·
Anne J. Gonzales-Luna
, Travis J. Carlson
, et al.
·
Drugs
·
36
PDF
Controversies in the Prevention and Treatment of Clostridioides difficile Infection in Adults: A Narrative Review
2023
·
Taryn B. Bainum
, Kelly R. Reveles
, et al.
·
Microorganisms
·
33
PDF
Microbiota restoration therapies for recurrent Clostridioides difficile infection reach an important new milestone
2024
·
Herbert L. DuPont
, Andrew W. DuPont
, et al.
·
Therapeutic Advances in Gastroenterology
·
31
Development and Validation of a Novel Microbiome-Based Biomarker of Post-antibiotic Dysbiosis and Subsequent Restoration
2022
·
Ken Blount
, Courtney Jones
, et al.
·
Frontiers in Microbiology
·
24
Protocol for a double-blind, randomised, placebo-controlled pilot study for assessing the feasibility and efficacy of faecal microbiota transplant in a paediatric Crohn’s disease population: PediCRaFT Trial
2019
·
Nikhil Pai
, Jelena Popov
, et al.
·
BMJ Open
·
24
PDF
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies
2023
·
Parul Berry
, Sahil Khanna
·
BioDrugs
·
23
Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!
2021
·
S. Khanna
·
Journal of Internal Medicine
·
23
PDF
Does the Donor Matter? Donor vs Patient Effects in the Outcome of a Next-Generation Microbiota-Based Drug Trial for Recurrent Clostridium Difficile Infection
2016
·
Arnab Ray
, Courtney Jones
·
Future Microbiology
·
23
Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent Clostridioides difficile Infection
2023
·
Romeo Papazyan
, Nicky Ferdyan
, et al.
·
Microorganisms
·
21
PDF
Practical Use of RBX2660 for the Prevention of Recurrent Clostridioides difficile Infection
2023
·
Paul Feuerstadt
, Jessica R. Allegretti
, et al.
·
The American Journal of Gastroenterology
·
19
Clostridioides Difficile: A Concise Review of Best Practices and Updates
2024
·
Abdelrahman Yakout
, Yan Bi
, et al.
·
Journal of Primary Care & Community Health
·
18
The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660
2022
·
Robert Orenstein
·
Infectious Diseases and Therapy
·
18
PDF
Show more works
View as search
Works count:
145
Citation count:
2,105
Year
Topic
Type